LGALS8 and ovarian serous adenocarcinoma: Labrie M et al. showed that plasma Gal-8 and Gal-9 levels were significantly increased in HGSOC patients compared to healthy controls, and higher plasma galectin-8 and galectin-9 levels were associated with a shorter 5-year disease-free survival (DFS) and 5-year OS (P=0.005), multivariate analysis further demonstrated that both plasma galectin-8 and galectin-9 could be promising biomarkers for poor prognosis in high grade serous ovarian cancer patients 171.